IRVING, Texas, USA — April 1, 2026
Caris Life Sciences® has announced the launch of Caris ChromoSeq™, the world’s first whole genome and whole transcriptome sequencing assay designed specifically for myeloid malignancies, marking a major advancement in precision oncology diagnostics. The innovative assay integrates ultra-deep whole genome sequencing (WGS) and whole transcriptome sequencing (WTS) to deliver a comprehensive, single-test solution for detecting complex genetic alterations in diseases such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN).
Comprehensive Genomic Profiling Enhances Diagnostic Accuracy
Myeloid malignancies are among the most genetically complex cancers, often requiring multiple diagnostic tests to identify mutations, chromosomal abnormalities, and structural variants. This fragmented diagnostic approach can delay treatment decisions and increase the risk of missing critical genomic information.
Caris ChromoSeq addresses these challenges by providing approximately 250x genome read depth and 40 million transcriptome reads, enabling high-resolution detection of clinically relevant biomarkers from a single sample. The assay consolidates multiple testing protocols into a unified diagnostic workflow, delivering results in an integrated, easy-to-interpret report within approximately seven days, significantly improving clinical decision-making speed and accuracy.
Favorable Safety Profile and Targeted Drug Delivery
Advertisement
HT-001 demonstrated a strong safety and tolerability profile, with no treatment discontinuations reported during the study. Pharmacokinetic analysis further showed that the therapy achieves approximately 99% lower systemic exposure compared to oral therapies, indicating a targeted delivery mechanism that minimizes systemic side effects while maximizing local therapeutic impact.
This localized approach is particularly important in oncology settings, where patients are often managing multiple therapies and are at increased risk of drug-drug interactions and cumulative toxicity. By reducing systemic exposure, HT-001 offers a safer and more effective solution for managing treatment-related dermatologic complications, addressing a significant unmet need in cancer care.
Advanced Sequencing Technology Streamlines Clinical Workflows
The ChromoSeq platform leverages next-generation sequencing (NGS), artificial intelligence (AI), and machine learning technologies to provide a holistic view of tumor biology, supporting clinicians in making timely and data-driven treatment decisions. By analyzing both genomic and transcriptomic data simultaneously, the assay offers a more complete molecular profile, enabling improved risk stratification, diagnosis, and therapy selection.
The test is designed to be used with bone marrow aspirate or peripheral blood samples, making it adaptable to real-world clinical settings. Its ability to replace multiple traditional diagnostic tests not only reduces laboratory complexity and turnaround times but also enhances operational efficiency in oncology care pathways. This streamlined approach aligns with the growing demand for integrated diagnostic solutions in precision medicine.
Precision Medicine Innovation Supports Oncology Advancement
The launch of Caris ChromoSeq underscores the company’s commitment to advancing precision medicine through innovative molecular profiling technologies. By combining multi-omic data analysis with AI-driven insights, Caris is enabling clinicians to better understand the molecular drivers of cancer and tailor treatment strategies accordingly.
This innovation is particularly significant for hematologic malignancies, where early and accurate diagnosis is critical for improving patient outcomes. The ability to deliver a comprehensive genomic assessment in a single test represents a transformative step in oncology diagnostics, supporting both clinical practice and drug development efforts.
Industry Impact and Future Outlook
The introduction of ChromoSeq reflects a broader shift toward integrated, high-throughput diagnostic platforms in oncology, where speed, accuracy, and data depth are essential for effective patient management. As precision medicine continues to evolve, technologies that combine genomics, transcriptomics, and AI analytics are expected to play a central role in shaping the future of cancer diagnosis and treatment.
From a cGxP perspective, the adoption of advanced diagnostic assays highlights the importance of validated laboratory processes, data integrity, and regulatory compliance in ensuring reliable and reproducible results. As healthcare systems increasingly rely on data-driven decision-making, solutions like ChromoSeq will be instrumental in improving patient outcomes and advancing personalized medicine.
Source: Caris Life Sciences press release
